| P50 | author | Malcolm Brenner | Q6742199 |
| | Gianpietro Dotti | Q89519252 |
| | Cliona M Rooney | Q96221187 |
| | Barbara Savoldo | Q109983471 |
| | Helen Heslop | Q17386041 |
| P2093 | author name string | Lan Zhang | |
| | Hinrich Abken | |
| | Aaron E Foster | |
| | Andreas Hombach | |
| | Antonio Di Stasi | |
| P2860 | cites work | Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. | Q53659254 |
| | Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor | Q56568324 |
| | Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice | Q57185434 |
| | Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin | Q67516432 |
| | Hodgkin's lymphoma | Q73154295 |
| | Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy | Q73523478 |
| | A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma | Q74286669 |
| | An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30 | Q74355983 |
| | Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas | Q74455956 |
| | Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product | Q77319231 |
| | Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody | Q80405355 |
| | Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience | Q83222464 |
| | Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 |
| | Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? | Q28207052 |
| | Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases | Q34052687 |
| | Immunodominant CD8 T cell response to Epstein-Barr virus | Q34415907 |
| | Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease | Q34534439 |
| | Epstein-Barr virus: exploiting the immune system | Q34572150 |
| | T-cell-receptor gene therapy | Q34718133 |
| | Targeting tumours with genetically enhanced T lymphocytes | Q35037678 |
| | Late complications of therapy of Hodgkin's disease: prevention and management | Q35616405 |
| | T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells | Q35848840 |
| | Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) | Q35849039 |
| | Current status of genetic modification of T cells for cancer treatment | Q36218988 |
| | Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice | Q36365868 |
| | Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease | Q36399791 |
| | Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy | Q36908563 |
| | Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease | Q38489712 |
| | A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells | Q40404804 |
| | Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. | Q40457809 |
| | Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. | Q40499531 |
| | CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. | Q40558080 |
| | Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications | Q40629249 |
| | Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes | Q40662000 |
| | Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients | Q40777664 |
| | High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma | Q40949380 |
| | Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? | Q41701819 |
| | Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects | Q41750120 |
| | RD114-pseudotyped oncoretroviral vectors. Biological and physical properties. | Q43679131 |
| | Involved-field radiotherapy for advanced Hodgkin's lymphoma. | Q44475165 |
| | Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy | Q45733496 |
| | Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection | Q45741637 |
| | Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients | Q45754081 |
| | Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease | Q45756934 |
| | Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes | Q45771097 |
| | T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect | Q47567565 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| | cytotoxicity | Q246181 |
| | immunotherapy | Q1427096 |
| P304 | page(s) | 2620-2630 | |
| P577 | publication date | 2007-05-16 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease | |
| P478 | volume | 110 | |